A Phase 1 interventional study of Ritonavir and saquinavir [Invirase] in HIV Infections, sponsored by Hoffmann-La Roche. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-03-29.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies testing ritonavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Ritonavir · HIV Infections.
Among the 124 studies testing ritonavir in HIV Infections, this one is the 101st largest by enrollment of the 119 interventional ones that give a count, is one of 14 that started in 2006, is one of 25 in phase 1, and was the 69th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →1 of the 124 studies testing ritonavir in HIV Infections is open now. Recruiting first, the newest first:
University College, London
Ages 4 wk–14 yrs
Ritonavir: first FDA approval 1996 (NORVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 38 · Phase 3 25 · Phase 4 24
First in 1998; this study’s year is marked. 14 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 46 across the 119 interventional studies. Of the 112 that completed or were terminated, 33 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 124 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
67 studies in HIV Infections by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 65 finished, 8 (12%) have results posted.
Among the 67 studies in HIV Infections by Hoffmann-La Roche, this one is the 47th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2006, is one of 8 in phase 1, and was the 56th registered.
Hoffmann-La Roche’s HIV Infections studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 124 studies testing ritonavir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 67 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This 2 arm study will assess the effect of moderate liver impairment on the pharmacokinetics of saquinavir and ritonavir at steady state following administration of saquinavir/ritonavir 1000mg/100mg po bid in HIV patients. Saquinavir/ritonavir will be administered concomitantly with 2 to 3 active nucleoside reverse transcriptase inhibitors. The study will compare a group of HIV patients without known liver disease and a group with moderate liver disease. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ritonavir · Drug: saquinavir [Invirase]
Drug: Ritonavir · Drug: saquinavir [Invirase]
100mg po bid
1000mg po bid
Area Under the Plasma Concentration-Time Curve From Time of Administration to 12 Hours After Dosing (AUC 0-12h) of Saquinavir (SQV) and Ritonavir (RTV)
Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. The pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the area under the plasma concentration-time curve from 0 to 12 hours after dosing (AUC (0-12h) of SQV and RTV The AUC (0-12hours) was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
Time frame: Pre-dose and at 0.5 hr, 1hr, 2hrs, 3hrs, 4hrs, 5hrs, 6hrs, 8hrs, 10hrs, and 12 hrs post-dose on Day 14
Maximum Observed Plasma Concentration (Cmax) of SQV and RTV
The plasma concentration (Cmax) is defined as maximum observed analyte concentration. The pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the maximum observed plasma concentration (C max) of SQV and Ritonavir RTV The Cmax was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
Time frame: Pre-dose and at 0.5 hr, 1hr, 2hrs, 3hrs, 4hrs, 5hrs, 6hrs, 8hrs, 10hrs, and 12 hrs post-dose on Day 14
Time of Maximum Plasma Concentration (Tmax) of SQV and RTV
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration. The Pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the time of maximum plasma concentration of SQV and RTV. The Tmax was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
Time frame: Pre-dose and at 0.5 hr, 1hr, 2hrs, 3hrs, 4hrs, 5hrs, 6hrs, 8hrs, 10hrs, and 12 hrs post-dose on Day 14
Terminal Half-life (T1/2) of SQV and RTV
Terminal half-life is the time measured for the plasma concentration to decrease by one half. The Pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the terminal half-life (T1/2) of SQV and RTV. The T1/2 was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
Time frame: Pre-dose and at 0.5 hr, 1hr, 2hrs, 3hrs, 4hrs, 5hrs, 6hrs, 8hrs, 10hrs, and 12 hrs post-dose on Day 14
Minimum Observed Plasma Concentration (Cmin) of SQV and RTV
Cmin is the minimum blood plasma concentration that a drug achieves. The Pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the minimum observed plasma concentration (C min) of SQV and RTV The Cmin was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
Time frame: Pre-dose and at 0.5 hr, 1hr, 2hrs, 3hrs, 4hrs, 5hrs, 6hrs, 8hrs, 10hrs, and 12 hrs post dose on Day 14
Plasma Clearance After Oral Administration (CL/F) of SQV and RTV
The CL/F is the oral clearance; that is clearance based on oral bioavailability. The Pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the plasma clearance after oral administration (CL/F)of SQV and RTV The CL/F was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
Time frame: Pre-dose and at 0.5 hr, 1hr, 2hrs, 3hrs, 4hrs, 5hrs, 6hrs, 8hrs, 10hrs, and 12 hrs post dose on Day 14
Volume of Distribution (Vd) of SQV and RTV
Vd is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. The pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the Vd of SQV and RTV The Vd was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
Time frame: Pre-dose and at 0.5 hr, 1hr, 2hrs, 3hrs, 4hrs, 5hrs, 6hrs, 8hrs, 10hrs, and 12 hrs post dose on Day 14
Cluster of Differentiation 4 (CD4 ) Count
The pharmacodynamic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the cluster of differentiation 4 (CD4) count in participants in each group.
Time frame: Screening (Day -35 to -1), pre-dose on Day 8, Day 14 and at follow up (Day 28-Day 35)
Number of Participants With the Indicated Grade 3 and Grade 4 Laboratory Parameters
Laboratory parameters specified in Clinical Operating Guidelines (COG) were summarized. AIDS Clinical Trial Group (ACTG) and American Heart Association (AHA) criteria were used to grade COG laboratory test values. Laboratory parameters for which an increase to Grade 3 (G3) or Grade 4 (G4) occurred are presented in the table below.
Time frame: Up to Day 35
Number Participants With Abnormal Vital Signs
Abnormal Vital signs included are high and low Pulse rate (PR), high and how Temperature (Temp), high and low Systolic Blood Pressure (SBP) and high and low Diastolic Blood Pressure (DBP). Vital signs (SBP, DBP, PR,Temp) were measured after participants were in a semi-supine position for at least 5 minutes.
Time frame: Up to Day 35
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Abnormal ECG findings included are high and low Heart Rate (HRT), high and low PQ/PR interval (PQ/PR), high and low QRS interval (QRS), high and low QT interval (QT), high and low QTCB interval (QTcB), high and low QTcF interval (QTcF), high and low RR interval (RR), high and low T Wave, high and low U Wave, high and low ECG. The 12 Lead ECG was recorded after participants were in a semi-supine position for at least 5 minutes. Only participants with abnormal ECG findings are presented in the table below.
Time frame: Up to Day 35
The study was conducted from 12 September 2006 to 09 April 2009 at 3 sites in US and 2 in Canada.
| Milestone | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| Started | 7 | 9 |
| Completed | 7 | 9 |
| Not completed | 0 | 0 |
Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. The pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the area under the plasma concentration-time curve from 0 to 12 hours after dosing (AUC (0-12h) of SQV and RTV The AUC (0-12hours) was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
| ng*hr/mL | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| AUC for SQV | 28518 ± 20157 | 24332 ± 24700 |
| AUC for RTV | 10985 ± 1723 | 9930 ± 5243 |
The plasma concentration (Cmax) is defined as maximum observed analyte concentration. The pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the maximum observed plasma concentration (C max) of SQV and Ritonavir RTV The Cmax was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
| ng/mL | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| Cmax of SQV | 4300 ± 2940 | 3610 ± 3000 |
| Cmax of RTV | 1500 ± 294 | 1460 ± 690 |
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration. The Pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the time of maximum plasma concentration of SQV and RTV. The Tmax was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
| hour | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| Tmax of SQV | 5.00 ± 1.83 | 5.00 ± 2.38 |
| Tmax of RTV | 4.29 ± 1.50 | 4.07 ± 1.75 |
Terminal half-life is the time measured for the plasma concentration to decrease by one half. The Pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the terminal half-life (T1/2) of SQV and RTV. The T1/2 was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
| hour | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| T1/2 of SQV | 3.31 ± 0.823 | 4.10 ± 1.90 |
| T1/2 of RTV | 3.80 ± 0.908 | 4.82 ± 2.82 |
Cmin is the minimum blood plasma concentration that a drug achieves. The Pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the minimum observed plasma concentration (C min) of SQV and RTV The Cmin was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
| ng/mL | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| Cmin of SQV | 965 ± 920 | 834 ± 870 |
| Cmin of RTV | 399 ± 172 | 418 ± 300 |
The CL/F is the oral clearance; that is clearance based on oral bioavailability. The Pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the plasma clearance after oral administration (CL/F)of SQV and RTV The CL/F was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
| L/hr | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| CL/F of SQV | 47.052 ± 20.254 | 84.416 ± 68.645 |
| CL/F of RTV | 9.289 ± 1.392 | 12.568 ± 5.885 |
Vd is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. The pharmacokinetic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the Vd of SQV and RTV The Vd was analyzed for SQV and RTV by non-compartmental methods, using WinNonlin.
| Litres | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| Vd of SQV | 213.294 ± 95.048 | 464.049 ± 334.460 |
| Vd of RTV | 50.232 ± 11.888 | 102.585 ± 112.579 |
The pharmacodynamic profile for following 14 days of administration with SQV/RTV 1000/100 mg BID included determining the cluster of differentiation 4 (CD4) count in participants in each group.
| cells/cubic millimeter | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| Screening; n=7, 9 | 540.000 ± 218.187 | 451.444 ± 249.011 |
| Day 8;n=6, 9 | 638.500 ± 254.358 | 558.000 ± 243.994 |
| Day 14;n=7, 9 | 683.571 ± 250.160 | 566.333 ± 257.484 |
| Follow up; n=6, 8 | 692.500 ± 150.045 | 567.625 ± 261.947 |
Laboratory parameters specified in Clinical Operating Guidelines (COG) were summarized. AIDS Clinical Trial Group (ACTG) and American Heart Association (AHA) criteria were used to grade COG laboratory test values. Laboratory parameters for which an increase to Grade 3 (G3) or Grade 4 (G4) occurred are presented in the table below.
| participants | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| ASAT (SGOT), (Hyper) G3 | 0 | 1 |
| ASAT (SGOT), (Hyper) G4 | 0 | 0 |
| Alkaline Phosphatase, (Hyper) G3 | 0 | 0 |
| Alkaline Phosphatase, (Hyper) G4 | 0 | 0 |
| ALAT (SGPT), (Hyper) G3 | 0 | 0 |
| ALAT (SGPT), (Hyper) G4 | 0 | 0 |
| Direct Bilirubin, (Hyper) G3 | 0 | 1 |
| Direct Bilirubin, (Hyper) G4 | 0 | 1 |
| Creatinine, (Hyper) G3 | 0 | 0 |
| Creatinine, (Hyper) G4 | 0 | 0 |
| Albumin, (Hypo) G3 | 0 | 0 |
| Albumin, (Hypo) G4 | 0 | 0 |
| Prothrombin Time seconds(Hyper) G3 | 0 | 1 |
| Prothrombin Time seconds (Hyper) G4 | 0 | 0 |
| Creatine Kinase, (Hyper) G3 | 0 | 1 |
| Creatine Kinase, (Hyper) G4 | 0 | 0 |
| Cholesterol, (Hyper) G3 | 0 | 0 |
| Cholesterol, (Hyper) G4 | 0 | 0 |
| Triglycerides, (Hyper) G3 | 2 | 0 |
| Triglycerides, (Hyper) G4 | 0 | 0 |
| Calcium, (Hypo) G3 | 0 | 0 |
| Calcium, (Hypo) G4 | 0 | 0 |
| Potassium, (Hypo) G3 | 0 | 0 |
| Potassium, (Hypo) G4 | 0 | 0 |
| Sodium, (Hypo) G3 | 0 | 0 |
| Sodium, (Hypo) G4 | 0 | 0 |
| Platelets, (Hypo) G3 | 0 | 0 |
| Platelets, (Hypo) G4 | 0 | 0 |
| Neutrophils, (Hypo) G3 | 0 | 1 |
| Neutrophils, (Hypo) G4 | 0 | 0 |
| Fasting Glucose, (Hyper) G3 | 0 | 0 |
| Fasting Glucose, (Hyper) G4 | 0 | 0 |
| Amylase, (Hyper) G3 | 0 | 1 |
| Amylase, (Hyper) G4 | 0 | 0 |
| Uric Acid, (Hyper) G3 | 0 | 2 |
| Uric Acid, (Hyper) G4 | 0 | 0 |
| Proteinuria 0 to 4+, (Hyper) G3 | 0 | 1 |
| Proteinuria 0 to 4+, (Hyper) G4 | 0 | 0 |
Abnormal Vital signs included are high and low Pulse rate (PR), high and how Temperature (Temp), high and low Systolic Blood Pressure (SBP) and high and low Diastolic Blood Pressure (DBP). Vital signs (SBP, DBP, PR,Temp) were measured after participants were in a semi-supine position for at least 5 minutes.
| participants | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| High PR | 0 | 0 |
| Low PR | 0 | 0 |
| High Temp | 0 | 0 |
| Low Temp | 0 | 0 |
| High-SBP | 1 | 1 |
| Low-SBP | 0 | 0 |
| High-DBP | 0 | 0 |
| Low-DBP | 1 | 2 |
Abnormal ECG findings included are high and low Heart Rate (HRT), high and low PQ/PR interval (PQ/PR), high and low QRS interval (QRS), high and low QT interval (QT), high and low QTCB interval (QTcB), high and low QTcF interval (QTcF), high and low RR interval (RR), high and low T Wave, high and low U Wave, high and low ECG. The 12 Lead ECG was recorded after participants were in a semi-supine position for at least 5 minutes. Only participants with abnormal ECG findings are presented in the table below.
| participants | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| HIGH- HRT ECG ; n=7, 9 | 1 | 0 |
| LOW- HRT ECG; n=7, 9 | 0 | 0 |
| HIGH- PQ (PR); n=7, 9 | 0 | 1 |
| LOW- PQ (PR); n=7, 9 | 0 | 0 |
| HIGH- QRS; n=7, 9 | 0 | 0 |
| LOW- QRS; n=7, 9 | 0 | 0 |
| HIGH- QT; n=7, 9 | 0 | 2 |
| LOW- QT; n=7, 9 | 0 | 0 |
| HIGH- QTcB; n=5, 8 | 0 | 2 |
| LOW- QTcB; n=5, 8 | 0 | 0 |
| HIGH- QTcF; n=5, 8 | 0 | 2 |
| LOW- QTcF; n=5, 8 | 0 | 0 |
| HIGH- RR; n=5, 8 | 0 | 0 |
| LOW- RR; n=5, 8 | 1 | 0 |
| HIGH- T WAVE; n=7, 9 | 0 | 0 |
| LOW- T WAVE; n=7, 9 | 0 | 0 |
| HIGH- U WAVE; n=1, 0 | 0 | 0 |
| LOW- U WAVE; n=1, 0 | 0 | 0 |
| HIGH- ECG; n=7, 9 | 0 | 0 |
| LOW- ECG; n=7, 9 | 0 | 0 |
Collected over Up to Day 35. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal Liver Function | — | 0/7 (0%) | 3/7 (42.9%) |
| Moderate Hepatic Impairment | — | 1/9 (11.1%) | 5/9 (55.6%) |
| Event | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/7 | 1/9 |
| Event | Normal Liver Function | Moderate Hepatic Impairment |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/7 | 1/9 |
| NauseaGastrointestinal disorders | 1/7 | 3/9 |
| FatigueGeneral disorders | 0/7 | 3/9 |
| Abdominal discomfortGastrointestinal disorders | 0/7 | 2/9 |
| NasopharyngitisInfections and infestations | 1/7 | 0/9 |
| Micturition UrgencyRenal and urinary disorders | 1/7 | 0/9 |
| Abdominal distensionGastrointestinal disorders | 0/7 | 1/9 |
| DyspepsiaGastrointestinal disorders | 0/7 | 1/9 |
| FlatulenceGastrointestinal disorders | 0/7 | 1/9 |
| VomitingGastrointestinal disorders | 0/7 | 1/9 |
| Age, Categorical(Participants) | Normal Liver Function | Moderate Hepatic Impairment | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 9 | 16 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Normal Liver Function | Moderate Hepatic Impairment | Total |
|---|---|---|---|
| Female | 2 | 3 | 5 |
| Male | 5 | 6 | 11 |
The record gives a start of Sep 2006, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 6 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ritonavir